Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast ...

Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...

US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...

Olema Pharmaceuticals (OLMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sam ...

Olema Pharmaceuticals, Inc. (OLMA), a clinical-stage biopharmaceutical company, Monday announced a new clinical trial collaboration ...

Olema Oncology and Novartis partner for Phase 3 trial combining palazestrant with Kisqali for breast cancer treatment. Olema ...

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) have been given an average rating of “Buy” by the six brokerages that are covering the company, Marketbeat reports.

To see multiple salmon species returning to Marin is a good sign of the health of the ocean and of possibly regional ...

Auctioneers say they have been instructed to recover overtime arrears due to 530 workers that have remained unpaid for 12 ...

Olema Oncology has announced that it has entered into a clinical trial collaboration and supply agreement with Novartis to ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.